At 9 months, the age at which the selenate treatment was started, Tg mice show already prominent signs of AD-like hippocampal Tau pathology as hyperphosphorylation, abnormal conformational changes, and aggregation of tau, associated with severe memory deficits and synaptic impairments. The gene discussed is MAPT; the disease is Alzheimer disease.